Showing results (41-50 of 77) with videos related to
Sort By:
Pageof 8
Viruses|March 26, 2013
Correlation of naturally occurring HIV-1 resistance to DEB025 with capsid amino acid polymorphismsPhilippe A Gallay, Roger G Ptak, Michael D Bobardt, et al.Plos One|August 12, 2015
The Novel Cyclophilin Inhibitor CPI-431-32 Concurrently Blocks HCV and HIV-1 Infections via a Similar Mechanism of ActionPhilippe A Gallay, Michael D Bobardt, Udayan Chatterji, et al.Epidemiology and Infection|September 2, 2003
Repeat capture-recapture studies as part of the evaluation of the surveillance of Legionnaires' disease in FranceA Nardone, B Decludt, S Jarraud, et al.The Open Virology Journal|March 16, 2018
Protection Efficacy of C5A Against Vaginal and Rectal HIV Challenges in Humanized MicePhilippe A Gallay, Udayan Chatterji, Aaron Kirchhoff, et al.Journal of Virology|October 20, 2006
Cell-free human immunodeficiency virus type 1 transcytosis through primary genital epithelial cellsMichael D Bobardt, Udayan Chatterji, Suganya Selvarajah, et al.Viruses|August 28, 2021
Protective Effects of Astodrimer Sodium 1% Nasal Spray Formulation against SARS-CoV-2 Nasal Challenge in K18-hACE2 MiceJeremy R A Paull, Carolyn A Luscombe, Alex Castellarnau, et al.Virology|July 13, 2004
Effect of polyanion-resistance on HIV-1 infectionMichael D Bobardt, Mercedes Armand-Ugón, Imma Clotet, et al.Plos One|February 5, 2019
The inhibitor apoptosis protein antagonist Debio 1143 Is an attractive HIV-1 latency reversal candidateMichael Bobardt, Joseph Kuo, Udayan Chatterji, et al.Antimicrobial Agents and Chemotherapy|November 11, 2015
C5A Protects Macaques from Vaginal Simian-Human Immunodeficiency Virus ChallengeRonald S Veazey, Udayan Chatterji, Michael Bobardt, et al.BMC Public Health|June 1, 2019
A cross sectional survey to estimate prevalence and associated factors of asthma on Reunion Island, Indian OceanJ-L Solet, C Raherison-Semjen, E Mariotti, et al.Pageof 8